Verification evidence is still being completed.
PDF / print export
VERAXA Biotech GmbH
Heidelberg, Germany
- Verified lead
- Christoph Antz
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Managing Director and Chief Executive Officer
- 2026 technical specialization
- Antibody Discovery, Antibody-Drug Conjugates, and Oncology Biologics Partnerships
- Review cycle
- 24 April 2026
- Full address
- Carl-Friedrich-Gauss-Ring 5, 69124 Heidelberg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- VERAXA Biotech official imprint listing Christoph Antz as Managing Director.
- Editorial note
- Heidelberg antibody and ADC platform biotech with named managing director, xlifesciences backing, and a documented partnership track record with Indivumed on precision oncology ADCs.
Antibody Discovery, Antibody-Drug Conjugates, and Oncology Biologics Partnerships
Public managing director disclosure, Published imprint and Handelsregister record, Documented Indivumed partnership
Heidelberg antibody and ADC platform biotech with named managing director, xlifesciences backing, and a documented partnership track record with Indivumed on precision oncology ADCs.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Heidelberg, Germany
VERAXA Biotech GmbH
Antibody Discovery, Antibody-Drug Conjugates, and Oncology Biologics Partnerships · Research-stage discovery and partnership delivery
Heidelberg antibody and ADC platform biotech with named managing director, xlifesciences backing, and a documented partnership track record with Indivumed on precision oncology ADCs.
- Lead
- Christoph Antz (verified ↗)
- Address
- Carl-Friedrich-Gauss-Ring 5, 69124 Heidelberg, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Research-stage discovery and partnership delivery
- Capabilities
- High-Throughput Antibody Screening · ADC Linker-Payload Platform · Target-to-ADC Partnership Model
- Founded
- 2019
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Christoph Antz
Managing Director and Chief Executive Officer
Full addressCarl-Friedrich-Gauss-Ring 5, 69124 Heidelberg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
VERAXA Biotech imprint listing Carl-Friedrich-Gauss-Ring 5 in Heidelberg.
Open sourceResearch-stage discovery and partnership delivery
Heidelberg, Germany. Antibody Discovery, Antibody-Drug Conjugates, and Oncology Biologics Partnerships. Review completed on 24 Apr 2026.
BfArM and EMA for any partner-led clinical development
Public managing director disclosure, Published imprint and Handelsregister record, Documented Indivumed partnership
Antibody Discovery, Antibody-Drug Conjugates, and Oncology Biologics Partnerships
Heidelberg antibody and ADC platform biotech with named managing director, xlifesciences backing, and a documented partnership track record with Indivumed on precision oncology ADCs.
Editorial note
VERAXA Biotech is an xlifesciences-backed Heidelberg biotech with a public managing director, a proprietary ADC platform, and documented partnership activity including Indivumed for precision-oncology ADC discovery.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
High-Throughput Antibody Screening
ADC Linker-Payload Platform
Target-to-ADC Partnership Model
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody screening platform
ADC conjugation chemistry
Partnership-led discovery pipeline
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is VERAXA Biotech GmbH located?
- VERAXA Biotech GmbH operates from Carl-Friedrich-Gauss-Ring 5, 69124 Heidelberg, Germany, Heidelberg, Germany.
- Who runs VERAXA Biotech GmbH?
- VERAXA Biotech GmbH is led by Christoph Antz, Managing Director and Chief Executive Officer. Verified 24 Apr 2026.
- What does VERAXA Biotech GmbH do?
- Heidelberg antibody and ADC platform biotech with named managing director, xlifesciences backing, and a documented partnership track record with Indivumed on precision oncology ADCs. Core capabilities: High-Throughput Antibody Screening, ADC Linker-Payload Platform, Target-to-ADC Partnership Model.
Editorial context
Related technical briefs
Briefs that name Heidelberg as a covered market or city.